Seeking Alpha

Mixed results for Shire in late stage lifitegrast trial

  • Shire (SHPG +0.8%) is out with top-line results from OPUS-2 (that's lifitegrast in dry eye patients).
  • Although the ophthalmic solution met its eye dryness co-primary endpoint, it did not meet the reduced corneal staining endpoint.
  • "We will be examining the totality of the data for lifitegrast in OPUS-2, as well as OPUS-1 and across the entire clinical trial program," CEO Flemming Ornskov says. (PR)
  • SHPG acquired the drug in the SARcode deal.
  • "The SARcode buyout was one of [Ornskov's] initial forays into ophthalmology," Jon Carroll notes, adding that "the mixed results in Phase 3 [are drawing] frowns from some analysts."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: